Pasithea Therapeutics Corp. KTTA
At closeNov 3, 2026, 6:47 PM EST
After hours · Nov 3, 6:47 PM ET
- YTD
- -58.91%
- 1 year
- -35.05%
- Market cap
- 17.71M
- EPS (ttm)
- -1.59
- Shares out
- 1.27M
- Forward P/E
- -3.75
- YTD return
- -58.91%
- 1-year return
- -35.05%
- Volume
- 21.34M
- Avg volume
- 228.50K
- Open
- 0.365
- Previous close
- 0.368
- Day's range
- 0.3477 – 0.5344
- 52-week range
- 0.281 – 2.06
- Beta
- 0.82
5D +0.0498 (+12.77%)
Key statistics
- Enterprise value
- -4.52M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.12
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -9.02M
- Total cash
- 7.97M
- Total debt
- 0
- Return on equity
- -63.25%
- Short % of float
- 1.40%
- 50-day average
- 3.39
- 200-day average
- 5.23
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -2.87 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -3.71 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -3.70 | — | — |
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pasithea.com
News
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Pasithea Therapeutics Says FDA Clears IND Application For Randomized, Placebo-Controlled Phase 2 Clinical Trial For PAS-004 In Patients With NF1 Associated Cutaneous Neurofibromas 
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF) 
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026 
Pasithea Therapeutics Presents Phase I Dose-Escalation Trial Of PAS-004 Inhibitor; Announces No Dose Limiting Toxicities Seen; No Participant Discontinued PAS-004; No Grade 3, Higher Observed 
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 2.7% – Time to Sell? 
12 Health Care Stocks Moving In Friday's After-Market Session 
Pasithea Sets November Debut For Early PAS-004 Clinical Trial Results 
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Your note
Sign in to keep a note on KTTA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| NOVAK ALFRED J | Director | Stock Award(Grant) | Jun 12, 2024 | 3,500 |
| STEINMAN LAWRENCE | Director | Purchase | Jun 1, 2023 | 1,327,170 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.52% | 6,567 | 17.47K | Sep 29, 2024 |
| Morgan Stanley | 0.12% | 1,500 | 3.99K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.05% | 601 | 1.60K | Sep 29, 2024 |
| Royal Bank of Canada | 0.02% | 250 | 665 | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.01% | 150 | 399 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 18 | 47 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.23% | 2,964 | 7.88K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 960 | 2.55K | Oct 30, 2024 |